Takeda Pharmaceutical Company Limited (NYSE:TAK) finished Thursday with a subtraction of -$0.22 to close at $12.94, a downside of -1.63 percent. An average of 2,530,478 shares of common stock have been traded in the last five days. There was a fall of -$0.52 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 2,411,675 shares traded, while the 50-day average volume stands at 2,397,774.
TAK stock has decreased by -5.46% in the last month. The company shares reached their 1-month lowest point of $12.93 on 09/23/22. With the stock rallying to its 52-week high on 02/18/22, shares of the company touched a low of $12.97 and a high of $17.19 in 52 weeks. It has reached a new high 16 times so far this year and lost -3.45% or -$0.70 in price. In spite of this, the price is down -24.69% from the 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now.
Takeda Pharmaceutical Company Limited (TAK) has a trailing price-to-earnings (P/E) ratio of 29.91. The stock’s beta is 0.73. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1.67, the price-to-book (PB) ratio at 0.92, and the price-to-cash flow ratio at 9.63.
The quick ratio of Takeda Pharmaceutical Company Limited for the recent quarter was 0.70, and the current ratio was 1.20, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.68 and a total debt to equity ratio of 0.73 for the recent quarter. Its gross profit as reported stood at $21.91 billion compared to revenue of $31.76 billion.
For the recent quarter, Takeda Pharmaceutical Company Limited had $266.65 million in cash and short-term investments compared to $512.16 million in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $1.69 billion in the quarter, while revenues were shrunk -100.94%.
From a technical analysis perspective, let’s take a brief look at Takeda Pharmaceutical Company Limited (TAK) price momentum. RSI 9-day as of the close on 22 September was 29.37%, suggesting the stock is oversold, with historical volatility in this time frame at 18.49%.
As of today, TAK’s price is $13.14 -3.90% or -$0.52 from its 5-day moving average. TAK is currently trading -7.81% lower than its 20-day SMA and -10.80% lower than its 100-day SMA. However, the stock’s current price level is -8.59% below the SMA50 and -6.75% below the SMA200.
The stochastic %K and %D were 14.45% and 16.10%, respectively, and the average true range (ATR) was 0.22. With the 14-day stochastic at 0.00% and the average true range at 0.22, the RSI (14) stands at 32.43%. The stock has reached -0.23 on the 9-day MACD Oscillator while the 14-day reading was at -0.33.
Cowen upgraded Takeda Pharmaceutical Company Limited (NYSE: TAK) to a an Outperform rating in its most recent analyst report. Previously, the stock was rated as a Market perform. The consensus rating for Takeda Pharmaceutical Company Limited (TAK) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell TAK, while 6 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 2 analysts, while 6 others rate it as a “buy”.
What is TAK’s price target for the next 12 months?
Analysts predict a range of price targets between $13.35 and $25.81, with a median target of $16.03. Taking a look at these predictions, the average price target given by analysts for Takeda Pharmaceutical Company Limited (TAK) stock is $16.68.